We are live on ! Find out more
TGTX icon

TG Therapeutics
TGTX

77 hedge funds and large institutions have $208M invested in TG Therapeutics in 2016 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 22 increasing their positions, 26 reducing their positions, and 18 closing their positions.

New
Increased
Maintained
Reduced
Closed

17% more capital invested

Capital invested by funds: $178M → $208M (+$30M)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

15% less funds holding

Funds holding: 91 → 77 (-14)

15% less repeat investments, than reductions

Existing positions increased: 22 | Existing positions reduced: 26

72% less first-time investments, than exits

New positions opened: 5 | Existing positions closed: 18

83% less call options, than puts

Call options by funds: $114K | Put options by funds: $653K

Holders
77
Holders Change
-14
Holders Change %
-15.38%
% of All Funds
2.05%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
5
Increased
22
Reduced
26
Closed
18
Calls
$114K
Puts
$653K
Net Calls
-$539K
Net Calls Change
+$308K

Top Buyers

Rank Fund Capital Flow
1
RCM
RA Capital Management
Massachusetts
+$639K
2
CCI
Columbus Circle Investors
+$370K
3
BFA
BlackRock Fund Advisors
California
+$355K
4
BIT
BlackRock Institutional Trust
California
+$349K
5
Morgan Stanley
Morgan Stanley
New York
+$338K

Top Sellers

Rank Fund Capital Flow
1
PAMU
Pictet Asset Management (UK)
United Kingdom
-$9.14M
2
UBS AM
UBS AM
Illinois
-$1.76M
3
Millennium Management
Millennium Management
New York
-$1.2M
4
OM
Opaleye Management
Massachusetts
-$1.06M
5
CS
Credit Suisse
Switzerland
-$750K
Name Holding Trade Value Shares
Change 		Change in
Stake
FAM
26
Fred Alger Management
New York
$542K +$12.2K +1,900 +3%
Swiss National Bank
27
Swiss National Bank
Switzerland
$515K – – –
AllianceBernstein
28
AllianceBernstein
Tennessee
$472K -$1.93K -300 -0.5%
Charles Schwab
29
Charles Schwab
California
$458K – – –
TA
30
Teachers Advisors
New York
$438K – – –
Citadel Advisors
31
Citadel Advisors
Florida
$311K -$25K -3,889 -9%
RhumbLine Advisers
32
RhumbLine Advisers
Massachusetts
$292K +$1.22K +190 +0.5%
VEA
33
Virtus ETF Advisers
New York
$273K – – –
FWM
34
Frontier Wealth Management
Missouri
$271K +$225K +35,000 New
Creative Planning
35
Creative Planning
Kansas
$233K -$13.2K -2,047 -6%
WMSA
36
Weiss Multi-Strategy Advisers
New York
$232K -$3.86K -600 -2%
MLICM
37
Metropolitan Life Insurance Company (MetLife)
New York
$204K +$6.08K +945 +4%
Mariner
38
Mariner
Kansas
$201K +$44.4K +6,900 +36%
Manulife (Manufacturers Life Insurance)
39
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$199K -$3.58K -557 -2%
Deutsche Bank
40
Deutsche Bank
Germany
$197K -$258K -40,096 -61%
RJA
41
Raymond James & Associates
Florida
$183K +$52.8K +8,212 +53%
AIG
42
American International Group
New York
$164K +$206 +32 +0.2%
BA
43
BlackRock Advisors
Delaware
$152K +$9.96K +1,549 +9%
Wells Fargo
44
Wells Fargo
California
$140K -$1.62K -252 -1%
BG
45
BlackRock Group
United Kingdom
$138K +$3.24K +504 +3%
BWP
46
Baldwin Wealth Partners
Massachusetts
$123K – – –
T. Rowe Price Associates
47
T. Rowe Price Associates
Maryland
$114K +$94.5K +14,700 New
Public Employees Retirement Association of Colorado
48
Public Employees Retirement Association of Colorado
Colorado
$103K – – –
Goldman Sachs
49
Goldman Sachs
New York
$89K +$73.6K +11,439 New
Susquehanna International Group
50
Susquehanna International Group
Pennsylvania
$86K -$122K -18,892 -63%
1
2
3 4

TGTX Hedge Fund Activity: Q3 2016 in Review

77 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in TG Therapeutics (TGTX) for Q3 2016, worth a combined $208M — up 17% from $178M a quarter earlier.

Sellers outnumbered buyers: 18 funds closed out of TGTX and 5 opened new positions — a net loss of 13 holders — while 26 trimmed existing stakes and 22 added.

The largest buyer was RA Capital Management, adding an estimated $639K. The largest seller was Pictet Asset Management (UK), exiting entirely with an estimated $9.14M sold.

  • 77 institutional investors held TG Therapeutics (TGTX) as of Q3 2016, down from 91 in Q2 2016.
  • Funds reported $208M of TG Therapeutics stock for Q3 2016, up 17% quarter-over-quarter.
  • 5 funds opened new TG Therapeutics positions in Q3 2016 and 18 closed out, a net change of -13 holders.
  • The largest TG Therapeutics buyer in Q3 2016 was RA Capital Management, an estimated $639K added.
  • The largest TG Therapeutics seller in Q3 2016 was Pictet Asset Management (UK), an estimated $9.14M sold.

Based on aggregated 13F filings for Q3 2016.